arrow
E

Emilio Bria

università cattolica del sacro cuore
H指数:62
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2026-09-080
OAAI
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study

真实世界中鳞状细胞肺癌新辅助化疗免疫治疗的安全性与有效性:一项欧洲多中心回顾性研究

2026-08-010
PRE
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
High Prevalence of Superficial Metastases Supports Percutaneous Ultrasound-Guided Biopsy for Diagnosis and Molecular Profiling of Advanced Lung Cancer: Results from a Prospective Cohort

浅表转移的高发生率支持经皮超声引导活检用于晚期肺癌的诊断和分子分型:一项前瞻性队列研究的结果

Cancers
IF4.4
2026-07-230
OA
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: a multicentric real-world study.

PIK3CA突变和内分泌抵抗性HR+/HER2-转移性乳腺癌的一线治疗效果:一项多中心真实世界研究。

2025-12-190
PREAI
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

BRCA突变HR阳性/HER2阴性晚期乳腺癌在接受CDK4/6抑制剂治疗后使用PARP抑制剂的实效性

2025-12-130
OAAI
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance

PI3K/mTORC2-RICTOR轴在早期鳞状非小细胞肺癌中的研究:基因组学、分子表达及其临床相关性

2025-11-070
OA
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

EGFR突变晚期非小细胞肺癌患者在接受一线奥希替尼治疗后,接受卡铂联合培美曲塞二线治疗的实际疗效:一项国际多中心队列研究

2025-10-160
PRE
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer

肿瘤抑制基因改变在非小细胞肺癌中的预后和预测意义

2025-10-060
OA
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib

NRG1变异体不确定意义(VUSes)在晚期非小细胞肺癌中的网络分析及其在EGFR突变患者接受一线奥希替尼治疗中的预后作用

2025-08-290
OAAI
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis

HR+/HER2−转移性乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂暴露后的循环基因组景观:一项回顾性多机构联盟分析

2025-08-160
OAAI
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

PD-L1低表达转移性非小细胞肺癌一线化疗联合免疫治疗方案的疗效与安全性:一项意大利观察性研究的结果

2025-07-120
OAAI
THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS

意大利MAURIS 3期B研究:阿替利珠单抗联合卡铂和依托泊苷治疗新诊断广泛期小细胞肺癌的3年研究结束结果

2025-07-090
OAAI
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

癌症临床试验中与FDA药物审批相关的患者入组标准及基线特征(2009–2023)

2025-06-260
OA